본문 바로가기
KERD
논문KCI 등재

Management of chronic hepatitis B patients in immunetolerant phase: what latest guidelines recommend

Grace Lai-Hung Wong
대한간학회 (The korean Association for the Study of the Liver)|2018.06|Clinical and Molecular Hepatology|제24권 제2호|pp. 108-113

2

조회

0

다운로드

10

인용

0

참고문헌

키워드

Hepatocellular carcinomaChronic hepatitis BImmune toleranceLiver fibrosisPositive HBeAg

초록

The natural history of chronic hepatitis B (CHB) is complex and may run through different immune phases that may overlap. In particulars, the immune-tolerant phase is the most interesting and not as well understood as we thought. The concept of true immune tolerance have been under challenged from immunology points of view. The major international guidelines have not yet reached a consensus on the definition of the immune-tolerant phase. While positive hepatitis B e antigen (HBeAg), high serum hepatitis B virus (HBV) DNA and normal serum alanine aminotransferase (ALT) levels are the three key features of this phase, some guidelines also put age into consideration. A new nomenclature, Phase 1 or HBeAg-positive chronic HBV infection, is given by the latest European Association for the Study of the Liver (EASL) published in April 2017. While current guidelines advise against starting antiviral treatment for immune-tolerant CHB patients, some new data suggest treating such patients may reduce the risk of liver fibrosis progression and hepatocellular carcinoma.

Abstract

The natural history of chronic hepatitis B (CHB) is complex and may run through different immune phases that may overlap. In particulars, the immune-tolerant phase is the most interesting and not as well understood as we thought. The concept of true immune tolerance have been under challenged from immunology points of view. The major international guidelines have not yet reached a consensus on the definition of the immune-tolerant phase. While positive hepatitis B e antigen (HBeAg), high serum hepatitis B virus (HBV) DNA and normal serum alanine aminotransferase (ALT) levels are the three key features of this phase, some guidelines also put age into consideration. A new nomenclature, Phase 1 or HBeAg-positive chronic HBV infection, is given by the latest European Association for the Study of the Liver (EASL) published in April 2017. While current guidelines advise against starting antiviral treatment for immune-tolerant CHB patients, some new data suggest treating such patients may reduce the risk of liver fibrosis progression and hepatocellular carcinoma.

참고문헌 (39)

  1. Schweitzer A, "Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013", Lancet, 386, pp.1546~1555 (2015)[DOI]
  2. Trepo C, "Hepatitis B virus infection", Lancet, 384, pp.2053~2063 (2014)[DOI]
  3. Terrault NA, "AASLD guidelines for treatment of chronic hepatitis B", Hepatology, 63, pp.261~283 (2016)[DOI]
  4. Sarin SK, "Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update", Hepatol Int, 10, pp.1~98 (2016)
  5. Bertoletti A, "Adaptive immunity in HBV infection", J Hepatol, 64(1 Suppl), pp.S71~S83 (2016)[DOI]
  6. European Association for the Study of the Liver, "EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection", J Hepatol, 67, pp.370~398 (2017)[DOI]
  7. Mason WS, "HBV DNA Integration and Clonal Hepatocyte Expansion in Chronic Hepatitis B Patients Considered Immune Tolerant", Gastroenterology, 151, pp.986~998 (2016)[DOI]
  8. 홍석진, "The Rate of Conversion from Immune-tolerant Phase to Early Immune-clearance Phase in Children with Chronic Hepatitis B Virus Infection", Pediatric Gastroenterology, Hepatology & Nutrition, 17(1), pp.41~46 (2014), 대한소아소화기영양학회
  9. 송병철, "Is it necessary to delay antiviral therapy for 3.6 months to anticipate HBeAg seroconversion in patients with HBeAg-positive chronic hepatitis B in endemic areas of HBV genotype C?", Clinical and Molecular Hepatology, 20(4), pp.355~360 (2014), 대한간학회
  10. Chan HL, "Hepatitis B virus genotype C is associated with more severe liver fibrosis than genotype B", Clin Gastroenterol Hepatol, 7, pp.1361~1366 (2009)[DOI]
  11. Kao JH, "Hepatitis B virus genotypes and spontaneous hepatitis B e antigen seroconversion in Taiwanese hepatitis B carriers", J Med Virol, 72, pp.363~369 (2004)[DOI]
  12. Chu CM, "Natural history of hepatitis B e antigen to antibody seroconversion in patients with normal serum aminotransferase levels", Am J Med, 116, pp.829~834 (2004)[DOI]
  13. Andreani T, "Chronic hepatitis B virus carriers in the immunotolerant phase of infection: histologic findings and outcome", Clin Gastroenterol Hepatol, 5, pp.636~641 (2007)[DOI]
  14. Wong GL, "Prediction of fibrosis progression in chronic viral hepatitis", Clin Mol Hepatol, 20, pp.228~236 (2014)[DOI]
  15. Wong GL, "Clinical factors associated with liver stiffness in hepatitis B e antigen-positive chronic hepatitis B patients", Clin Gastroenterol Hepatol, 7, pp.227~233 (2009)[DOI]
  16. Chan HL, "Alanine aminotransferase-based algorithms of liver stiffness measurement by transient elastography (Fibroscan) for liver fibrosis in chronic hepatitis B", J Viral Hepat, 16, pp.36~44 (2009)[DOI]
  17. Wong GL, "Personalized management of cirrhosis by non-invasive tests of liver fibrosis", Clin Mol Hepatol, 21, pp.200~211 (2015)[DOI]
  18. Nguyen MH, "Histological disease in Asian-Americans with chronic hepatitis B, high hepatitis B virus DNA, and normal alanine aminotransferase levels", Am J Gastroenterol, 104, pp.2206~2213 (2009)[DOI]
  19. Wong GL, "Liver fibrosis progression in chronic hepatitis B patients positive for hepatitis B e antigen: a prospective cohort study with paired transient elastography examination", J Gastroenterol Hepatol, 28, pp.1762~1769 (2013)[DOI]
  20. Yang HI, "Hepatitis B e antigen and the risk of hepatocellular carcinoma", N Engl J Med, 347, pp.168~174 (2002)[DOI]
  21. Yang HI, "Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACHB): development and validation of a predictive score", Lancet Oncol, 12, pp.568~574 (2011)[DOI]
  22. Wong GL, "Accuracy of risk scores for patients with chronic hepatitis B receiving entecavir treatment", Gastroenterology, 144, pp.933~944 (2013)[DOI]
  23. Wong VW, "Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers", J Clin Oncol, 28, pp.1660~1665 (2010)[DOI]
  24. Yuen MF, "Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B", J Hepatol, 50, pp.80~88 (2009)[DOI]
  25. Wong GL, "Liver stiffness-based optimization of hepatocellular carcinoma risk score in patients with chronic hepatitis B", J Hepatol, 60, pp.339~345 (2014)[DOI]
  26. Kim GA, "High risk of hepatocellular carcinoma and death in patients with immunetolerant-phase chronic hepatitis B", Gut (2017)
  27. Chan HL, "Effects of tenofovir disoproxil fumarate in hepatitis B e antigenpositive patients with normal levels of alanine aminotransferase and high levels of hepatitis B virus DNA", Gastroenterology, 146, pp.1240~1248 (2014)[DOI]
  28. Wong VW, "Fouryear Outcomes After Cessation of Tenofovir in Immune-tolerant Chronic Hepatitis B Patients", J Clin Gastroenterol (2017)
  29. Wong GL, "Update of liver fibrosis and steatosis with transient elastography (Fibroscan)", Gastroenterol Rep (Oxf), 1, pp.19~26 (2013)[DOI]
  30. Wong GL, "Transient elastography: Kill two birds with one stone?", World J Hepatol, 5, pp.264~274 (2013)[DOI]
  31. Wong GL, "Noninvasive algorithm of enhanced liver fibrosis and liver stiffness measurement with transient elastography for advanced liver fibrosis in chronic hepatitis B", Aliment Pharmacol Ther, 39, pp.197~208 (2014)[DOI]
  32. Wong GL, "Development of a non-invasive algorithm with transient elastography (Fibroscan) and serum test formula for advanced liver fibrosis in chronic hepatitis B", Aliment Pharmacol Ther, 31, pp.1095~1103 (2010)[DOI]
  33. "Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection"[URL]
  34. Liu CP, "Factors associated with mother-to-child transmission of hepatitis B virus despite immunoprophylaxis", Intern Med, 54, pp.711~716 (2015)[DOI]
  35. Wen WH, "Motherto-infant transmission of hepatitis B virus infection: significance of maternal viral load and strategies for intervention", J Hepatol, 59, pp.24~30 (2013)[DOI]
  36. Chen HL, "Efficacy of maternal tenofovir disoproxil fumarate in interrupting mother-to-infant transmission of hepatitis B virus", Hepatology, 62, pp.375~386 (2015)[DOI]
  37. Pan CQ, "Tenofovir to Prevent Hepatitis B Transmission in Mothers with High Viral Load", N Engl J Med, 374, pp.2324~2334 (2016)[DOI]
  38. Chang Y, "Nucleos(t) ide Analogue Treatment for Adult Patients with HBeAg-positive Chronic Infection with Genotype C Hepatitis B Virus: A Nationwide Real-life Study", J Infect Dis (2017)
  39. Wong GL, "Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis", Hepatology, 58, pp.1537~1547 (2013)[DOI]

관련 논문AI추천

Long-term prognosis and the need for histologic assessment of chronic hepatitis B in the serological immune-tolerant phase김영석, 유정주, Han Ah Lee, Jieun Lee, Ji Eun Moon, Sang Gyune Kim, Soo Young Park, Yeon Seok Seo, Yu Rim Lee대한간학회 · Clinical and Molecular Hepatology2023 · 제29권 제2호Negligible risks of hepatocellular carcinoma during biomarker-defined immune-tolerant phase for patients with chronic hepatitis B김도영, 김범경, 김승업, 박준용, 안상훈, 이혜원, 한광협, Jae Seung Lee, Mi Young Jeon대한간학회 · Clinical and Molecular Hepatology2021 · 제27권 제2호The role of different viral biomarkers on the management of chronic hepatitis BJames Fung, Lung-Yi Mak, Man-Fung Yuen, Rex Wan-Hin Hui, Wai Kay Seto대한간학회 · Clinical and Molecular Hepatology2023 · 제29권 제2호Comparison of clinical practice guidelines for the management of chronic hepatitis B: When to start, when to change, and when to stopDong Hyun Sinn, Eileen L. Yoon, Hana Park, Hyung Joon Yim, Hyun Woong Lee, Jeong-Hoon Lee, Ji Hoon Kim, Jung Hyun Kwon, Jun Yong Park, Sae Hwan Lee대한간학회 · Clinical and Molecular Hepatology2020 · 제26권 제4호Management of Chronic Hepatitis B with Nucleoside or Nucleotide Analogues: A Review of Current Guidelines유병철, 최문석거트앤리버 소화기연관학회협의회 · Gut and Liver2010 · 제4권 제1호Update on the treatment navigation for functional cure of chronic hepatitis B: Expert consensus 2.0Apichat Kaewdech, Di Wu, Fengmin Lu, Fu-sheng Wang, Guiqiang Wang, Hong Ren, Jia-Horng Kao, Junqi Niu, Man-Fung Yuen, Meifang Han, Motoyuki Otsuka, Patrick T.F. Kennedy, Paul Yien Kwo, Peng Hu, Qin Ning, Sainan Shu, Sang Hoon Ahn, Teerha Piratvisuth, Weiming Yan, Wenhong Zhang, Wenhui Li, Xiaojing Wang, Yasuhito Tanaka, Young-Suk Lim, Zhenghong Yuan, Zhiliang Gao대한간학회 · Clinical and Molecular Hepatology2025 · 제31권 제1호

이 간행물의 다른 논문 (8건)

Epidemiology of alcoholic liver disease in KoreaJae Young Jang, 김동준pp. 93-99Microbiota, a key player in alcoholic liver diseaseDragos Ciocan, Anne-Marie Cassardpp. 100-107Strategic application of radiotherapy for hepatocellular carcinoma성진실, Seo Hee Choipp. 114-134Comparison of surgical resection versus transarterial chemoembolization with additional radiation therapy in patients with hepatocellular carcinoma with portal vein invasion정진욱pp. 135-136Journal metrics of Clinical and Molecular Hepatology based on the Web of Science Core CollectionSun Huhpp. 137-143
원문 보기